Returning guest, Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses Azeliragon and the launch of investigator-led clinical studies focusing on a combination with radiosurgery in patients with brain metastases, front-line treatment for glioblastoma, metastatic pancreatic cancer and treatment of patients hospitalized with COVID-19 and pneumonia to prevent acute kidney injury.

#CantexPharmaceuticals

STEPHEN G. MARCUS, M.D., CHIEF EXECUTIVE OFFICER    Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.      

In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a chronic lymphocytic leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.

Dr. Michael R. Jaff, Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific and Dr. Peter Monteleone, MD, FACC, FSCAI an interventional cardiologist and vascular medicine physician at Ascension Texas Cardiovascular in Austin, Texas and principal investigator of the REAL-PE study talk about the study results and the potential for real-world data to improve patient care in pulmonary embolism treatment and beyond.

#REALPEStudy #EKOS #Truveta

Michael R. Jaff, DO is the Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific. A former professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine. He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries. Dr. Jaff has published extensively in the field of Vascular Medicine with over 325 peer reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).

David Berman, Head of Research and Development at Immunocore discusses the 3-year overall survival data from the  KIMMTRAK Phase 3 trial that  was presented at the European Society of Medical Oncology (ESMO) 2023  for their FDA approved treatment for uveal melanoma, a very deadly type of cancer in the eye. It was the first-ever approved treatment in the space.

#Immunocore

Dr. David Berman is Head of Research and Development. Over his career, David has worked on multiple immuno-oncology (IO) programs at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca IO Franchise, responsible for the strategy and execution of the Company’s late stage IO program.   Prior to that, he was Head of the early stage oncology program at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including as Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action and predict benefit from IO therapies.

David received a Bachelor’s of Science from the Massachusetts Institute of Technology and MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins Hospital.